India, June 24 -- Glenmark Pharmaceuticals (Glenmark) launched TEVIMBRA' (tislelizumab) in India following the approval by Central Drugs Standard Control Organization (CDSCO).TEVIMBRA is a uniquely designed anti-PD-1 monoclonal antibody developed by BeiGene (now BeOne Medicines), a global oncology leader committed to delivering advanced treatments for cancer patients worldwide. It is indicated for the treatment of first-line locally advanced or metastatic non-small cell lung cancer (NSCLC) in combination with chemotherapy and second-line treatment of locally advanced or metastatic NSCLC and esophageal squamous cell carcinoma (ESCC) as monotherapy.This launch marks Glenmark's first foray into immune-oncology in India and is a major milestone...